Overview

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

Status:
Active, not recruiting

Trial end date:
2024-10-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the effect of ixazomib maintenance therapy on progression free survival (PFS) compared with placebo, in participants with NDMM who have had a major response (complete response [CR], very good partial response [VGPR], or partial response [PR]) to initial therapy and who have not undergone SCT.

Phase:

Phase 3

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Treatments:

Glycine
Ixazomib